Inari Medical, Inc. (NASDAQ:NARI) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC increased its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 32.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 95,223 shares of the company’s stock after acquiring an additional 23,286 shares during the quarter. Jane Street Group LLC owned approximately 0.16% of Inari Medical worth $3,927,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after purchasing an additional 435 shares during the last quarter. GAMMA Investing LLC increased its position in Inari Medical by 67.2% in the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after buying an additional 473 shares during the period. KBC Group NV lifted its stake in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after buying an additional 522 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Inari Medical during the second quarter valued at $104,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Stock Down 2.0 %

NASDAQ:NARI opened at $55.03 on Thursday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.10. The firm has a market cap of $3.22 billion, a P/E ratio of -40.76 and a beta of 0.97. The business’s 50-day moving average price is $49.30 and its 200 day moving average price is $48.04.

Insider Transactions at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00. Following the completion of the sale, the director now directly owns 561,233 shares of the company’s stock, valued at $28,089,711.65. This trade represents a 6.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 445,310 shares in the company, valued at $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 203,000 shares of company stock valued at $10,362,000 in the last quarter. Insiders own 10.60% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on NARI shares. Leerink Partners started coverage on shares of Inari Medical in a report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price objective on the stock. Truist Financial raised their price target on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday. Piper Sandler boosted their price objective on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 29th. Oppenheimer assumed coverage on Inari Medical in a research report on Tuesday. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.80.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.